Pfizer's Viagra fails in Phase III lung trial
This article was originally published in Scrip
Executive Summary
Pfizer's Viagra/Revatio (sildenafil) failed to meet its primary endpoint in a Phase III trial of patients with advanced idiopathic pulmonary fibrosis (IPF). Citing "small but significant effects" on secondary endpoints, however, investigators from The Idiopathic Pulmonary Fibrosis Clinical Research Network suggest that further studies of the drug for this indication are warranted.